摘要 |
<p>The present invention provides a compound of formula (I) wherein: R<sup>1</sup> is a group selected from -CH<sub>2</sub>OH, -NHC(O)H and R<sup>2</sup> is a hydrogen atom; or R<sup>1</sup> together with R<sup>2</sup> form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R<sup>1</sup> and the carbon atom is bound to the carbon atom in the phenyl ring holding R<sup>2</sup>; R<sup>3</sup> is selected from hydrogen and halogen atoms or groups selected from -SO-R<sup>5</sup>, -SO<sub>2</sub>- R<sup>5</sup>, -NH-CO-NH<sub>2</sub>, -CO-NH<sub>2</sub>, hydantoino, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy and -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; R<sup>4</sup> is selected from hydrogen atoms, halogen atoms and C<sub>1-4</sub>alkyl groups; R<sup>5</sup> is a C<sub>1-4</sub>alkyl group or C<sub>3-8</sub> cycloalkyl; R<sup>6</sup> is independently selected from hydrogen atoms and C<sub>1-4</sub>alkyl groups; n, p and q are independently 0, 1 , 2, 3 or 4; m and s are independently 0, 1 , 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11 , 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.</p> |